Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters

International Journal of Cancer

Volumn 118, Issue 8, 2006, Pages 1954-1962

  Zirn, B ^a   Hartmann, O ^b   Samans, B ^b   Krause, M ^b   Wittmann, S ^a   Mertens, F ^c   Graf, N ^d   Eilers, M ^b   Gessler, M ^a,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

E2F; Microarray; Nephroblastoma; Retinoic acid; Wilms tumor

Indexed keywords

COMPLEMENTARY DNA; RETINOIC ACID;

ARTICLE; CANCER CHEMOTHERAPY; CENPF GENE; CLINICAL PROTOCOL; CONTROLLED STUDY; CTGF GENE; DNA FINGERPRINTING; DNA MICROARRAY; EZH2 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MYCN GENE; NEPHROBLASTOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RARRES3 GENE; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; TRIM22 GENE; TUMOR GROWTH; UNITED STATES;

DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRETINOIN; WILMS TUMOR;

EID: 33645236966     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21564     Document Type: Article

References (39)

1. Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms' tumor. The SIOP studies. International Society of Pediatric Oncology. Urol Clin North Am 2000;27:443-54.
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990;343:774-8.
3. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J, von Knebel Doeberitz M. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-2.
4. Maiti S, Alam R, Amos CI, Huff V. Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res 2000;60:6288-92.
5. Gessler M, Konig A, Arden K, Grundy P, Orkin S, Sallan S, Peters C, Ruyle S, Mandell J, Li F, et al. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors. Hum Mutat 1994;3:212-22.
6. Hill DA, Shear TD, Liu T, Billups CA, Singh PK, Dome JS. Clinical and biologic significance of nuclear unrest in Wilms tumor. Cancer 2003;97:2318-26.
7. Grundy RG, Pritchard J, Scambler P, Cowell JK. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. Br J Cancer 1998;78:1181-7.
8. Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, Kartal A, Flynn D, Wiedemeyer R, Schwab M, Schafer H, Christiansen H, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002;2:377-86.
9. Yang YH, Dudoit S, Luu P. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:15.
10. Benjamini Y, Hochberg YH. Controlling the false discovery rate: a practical and powerful approach for multiple testing. J R Statist Soc B 1995;57:289-300.
11. Callow MJ, Dudoit S, Gong EL, Speed TP, Rubin EM. Microarray expression profiling identifies genes with altered expression in HDL-deficient mice. Genome Res 2000;10:2022-9.
12. Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for p-value adjustment. New York: Wiley, 1993.
13. Ross I, Gentleman RR. A language for data analysis and graphics. J Comput Graphical Stat 1996;5:299-314.
14. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18:207-8.
15. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
16. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 2002;38:79-82.
17. Weirich A, Leuschner I, Harms D, Vujanic GM, Troger J, Abel U, Graf N, Schmidt D, Ludwig R, Voute PA. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol 2001;12:311-9.
18. Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene 2003;22:6497-507.
19. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
20. Takahashi M, Yang XJ, Lavery TT, Furge KA, Williams BO, Tretiakova M, Montag A, Vogelzang NJ, Re GG, Garvin AJ, Soderhall S, Kagawa S, et al. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res 2002;62:6598-605.
21. Li W, Kessler P, Williams BR. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene 2005;24:457-68.
22. Williams RD, Hing SN, Greer BT, Whiteford CC, Wei JS, Natrajan R, Kelsey A, Rogers S, Campbell C, Pritchard-Jones K, Khan J. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 2004;41:65-79.
23. Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, Gray SG, Knapp R, Anema J, Kahnoski R, Nicol D, Vogelzang NJ, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003;22:6810-8.
24. Rigolet M, Faussillon M, Baudry D, Junien C, Jeanpierre C. Profiling of differential gene expression in Wilms tumor by cDNA expression array. Pediatr Nephrol 2001;16:1113-21.
25. Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R, Klein U, Tycko B. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 2002;160:2181-90.
26. Arcellana-Panlilio MY, Egeler RM, Ujack E, Pinto A, Demetrick DJ, Robbins SM, Coppes MJ. Decreased expression of the INK4 family of cyclin-dependent kinase inhibitors in Wilms tumor. Genes Chromosomes Cancer 2000;29:63-9.
27. Dome JS, Chung S, Bergemann T, Umbricht CB, Saji M, Carey LA, Grundy PE, Perlman EJ, Breslow NE, Sukumar S. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res 1999;59:4301-7.
28. Baudry D, Faussillon M, Cabanis MO, Rigolet M, Zucker JM, Patte C, Sarnacki S, Boccon-Gibod L, Junien C, Jeanpierre C. Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour. Oncogene 2002;21:5566-73.
29. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, Mathoera RB, Nijman JM, van der Kwast TH. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 2003;56:107-13.
30. Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer CG, Albrecht S, Von Schweinitz D, Pietsch T. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest 2003;83:429-34.
31. Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, Brodeur GM, Evans AE. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol 2001;19:689-96.
32. Grundy P, Telzerow P, Moksness J, Breslow NE. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis. Med Pediatr Oncol 1996;27:429-33.
33. Stanhope-Baker P, Williams BR. Identification of connective tissue growth factor as a target of WT1 transcriptional regulation. J Biol Chem 2000;275:38139-50.
34. Park DJ, Vuong PT, de Vos S, Douer D, Koeffler HP. Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood 2003;102:3727-36.
35. Tice DA, Szeto W, Soloviev I, Rubinfeld B, Fong SE, Dugger DL, Winer J, Williams PM, Wieand D, Smith V, Schwall RH, Pennica D, et al. Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J Biol Chem 2002;277:14329-35.
36. Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene 2005;24:5246-51.
37. Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 2001;15:267-85.
38. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-35.
39. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002;3:11-20.